Related Experiment Video
Updated: May 11, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Waldenström macroglobulinaemia: the key questions
Anita D'Souza1, Stephen Ansell, Craig Reeder
1Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
British Journal of Haematology
|May 9, 2013
Summary
This review covers Waldenström disease, offering updated insights on diagnosis, prognosis, and advanced treatment options. It includes current therapies discussed at the 7th International Workshop for Waldenström Macrogloblobulinaemia.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma.
- Understanding key issues in WM is crucial for patient management.
Purpose of the Study:
- To provide a concise overview of Waldenström disease.
- To update information on diagnosis, prognosis, and therapy indications.
- To present current therapeutic strategies for WM.
Main Methods:
- Question-and-answer format review.
- Inclusion of data from the 7th International Workshop for Waldenström Macrogloblobulinaemia.
Main Results:
- Key diagnostic criteria and prognostic factors are updated.
- Current state-of-the-art treatment indications are detailed.
- Recent therapeutic advancements in WM are summarized.
Conclusions:
- The review offers a current, accessible guide to Waldenström disease management.
- It highlights the latest therapeutic approaches for WM patients.
- This resource aids clinicians in diagnosing and treating WM effectively.
